BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 8, 2026
Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

AtheroGenics Signs Agreement With AstraZeneca For Up To $1B

Dec. 23, 2005
By Jennifer Boggs
With the end of 2005 less than two weeks away, the biggest collaborative biotech deal of the year came in just under the wire. (BioWorld Today)
Read More

Acologix's Series C: $25M For AC-820 Phase III Trial

Dec. 22, 2005
By Jennifer Boggs

Acologix's Series C: $25M For AC-820 Phase III Trial

Dec. 22, 2005
By Jennifer Boggs

Memory Gains $3.2M For Bipolar Work, Reports Positive AD Data

Dec. 21, 2005
By Jennifer Boggs

Onyx's Nexavar Wins FDA Approval In Kidney Cancer

Dec. 21, 2005
By Jennifer Boggs

Onyx's Nexavar Wins FDA Approval In Kidney Cancer

Dec. 21, 2005
By Jennifer Boggs

Memory Gains $3.2M For Bipolar Work, Reports Positive AD Data

Dec. 21, 2005
By Jennifer Boggs

Palatin Stops NeutroSpec Sales To Investigate Reported Deaths

Dec. 20, 2005
By Jennifer Boggs

Palatin Stops NeutroSpec Sales To Investigate Reported Deaths

Dec. 20, 2005
By Jennifer Boggs

ImaRx Adds $15M For Stroke Studies, Product Acquisition

Dec. 19, 2005
By Jennifer Boggs
View All Articles by Jennifer Boggs

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing